AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior version and listing of claims in the application:

Claim 1   (currently amended): A method for treating a taxol-induced gut disorder in a mammal comprising administering to [[the]] an mammal having a taxol-induced gut disorder an effective amount of an agonist anti-trkC antibody, wherein the agonist anti-trkC antibody binds to a mammalian trkC receptor and activates the trkC receptor.

Claim 2   (original): The method of claim 1, wherein the agonist anti-trkC antibody binds human trkC.

Claim 3   (original): The method of claim 1, wherein the agonist anti-trkC antibody binds human trkC and rodent trkC.

Claim 4   (original): The method of claim 1, wherein the agonist anti-trkC antibody binds an epitope in domain 5 of trkC.

Claim 5   (original): The method of claim 4, wherein the trkC is human trkC.

Claim 6   (original): The method of claim 1, wherein the agonist anti-trkC antibody is a human antibody.

Claim 7   (original): The method of claim 1, wherein the agonist anti-trkC antibody is a humanized antibody.

Claim 8   (original): The method of claim 1, wherein the agonist anti-trkC antibody is a monoclonal antibody.

Claim 9   (original): The method of claim 1, wherein the agonist anti-trkC antibody comprises CDRs from heavy chain variable region shown in SEQ ID NO:1.

Claim 10   (original): The method of claim 1, where in the agonist anti-trkC antibody comprises CDRs from light chain variable region shown in SEQ ID NO:2.

Claim 11   (original): The method of claim 1, wherein the agonist anti-trkC antibody comprises CDRs from heavy chain variable region shown in SEQ ID NO:1 and CDRs from light chain variable region shown in SEQ ID NO:2.

Claim 12   (original): The method of claim 1, wherein the agonist anti-trkC antibody comprises the heavy chain variable region shown in SEC ID NO:1 and the light chain variable region shown in SEQ ID NO:2.

Claims 13-14 (canceled)

Claim 15   (new): The method of claim 1, wherein the mammal is a human.